INOVIQ Ltd

Company Profile

Sector

Healthcare

Industry

Diagnostics & Research

Employees

N/A

Website

www.inoviq.com

Country

Australia

Exchange

ASX

Founded 2016Notting Hill, Australia

INOVIQ develops and commercializes diagnostic and exosome-based products to enhance the diagnosis and treatment of cancer and other diseases in Australia and the United States. It offers hTERT ICC test, an immunocytochemistry test used as an adjunct to urine cytology testing for bladder cancer

EXO-NET, an EV isolation tool for biomarker discovery and diagnostic development. It offers non-invasive, diagnostics using its proprietary exosome develops technologies for improved screening, diagnosis, treatment selection and monitoring of cancer and diseases. Founded in 2016 and headquartered in Notting Hill, Australia, INOVIQ was formerly known as BARD1 Life Sciences Limited before rebranding in December 2021.

Key Stats

52-Week Range

A$0.18A$0.56

Beta1.62

Trailing P/EN/A

Forward P/E-4.75

Trailing EPS-0.06

Avg Volume

Earnings & Analyst

Next EarningsN/A

EPS EstimateN/A

Target Mean PriceA$0.70

RecommendationBuy

Recommendation Mean2.00

Recent SEC Filings

SEC filings for this ticker are not available yet.